Update on heparin: What do we need to know?

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 2, 2010, Pages 199-207

  Weitz, Daniel S ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Fondaparinux; Heparin; Low molecular weight heparin; Parenteral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NU 172; OTAMIXABAN; PLACEBO; PROTAMINE SULFATE; RB 006; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOPULMONARY BYPASS; CATHETER THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTAMINATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SECONDARY PREVENTION; THROMBOCYTE COUNT; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 77949914071     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0411-6     Document Type: Conference Paper

References (51)

1. J Hirsh KA Bauer MB Donati M Gould MM Samama JI Weitz American College of Chest Physicians 2008 Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 141S 159S 10.1378/chest.08-0689 1:CAS:528:DC%2BD1cXptVKiu7w%3D 18574264
2. JI Weitz 1997 Low-molecular-weight heparins N Engl J Med 337 688 698 10.1056/NEJM199709043371007 1:CAS:528:DyaK2sXmt1Wqtbc%3D 9278467 (Pubitemid 27375477)
3. E Young M Prins MN Levine J Hirsh 1992 Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 639 643 1:STN:280:DyaK38zns1OmsA%3D%3D 1509402
4. E Young B Cosmi J Weitz J Hirsh 1993 Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins Thromb Haemost 70 625 630 1:CAS:528:DyaK2cXksFWmuw%3D%3D 8115988
5. E Young P Wells S Holloway J Weitz J Hirsh 1994 Ex-vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin Thromb Haemost 71 300 304 1:CAS:528:DyaK2cXlt1Cms78%3D 8029793
6. R Othieno M Abu Affan E Okpo 2007 Home versus in-patient treatment for deep vein thrombosis Cochrane Database Syst Rev 18 CD003076
7. S Siragusa B Cosmi F Piovella J Hirsh JS Ginsberg 1996 Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis Am J Med 100 269 277 10.1016/S0002-9343(97)89484-3 1:CAS:528:DyaK28XitlOisbo%3D 8629671 (Pubitemid 26111623)
8. E Rocha MA Martinez-Gonzalez R Montes C Panizo 2000 Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis Haematologica 85 935 942 1:CAS:528: DC%2BD3cXnslegsbs%3D 10980632
9. LR Dolovich JS Ginsberg JD Douketis AM Holbrook G Cheah 2000 A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency Arch Intern Med 160 181 188 10.1001/archinte.160.2.181 1:STN:280: DC%2BD3c7ht1arsA%3D%3D 10647756
10. ML Louzada H Majeed PS Wells 2009 Efficacy of low-molecular-weight heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Thromb Res 123 837 844 10.1016/j.thromres.2008.09. 002 1:CAS:528:DC%2BD1MXjvV2nur8%3D 18977517
11. FF van Doormaal GE Raskob BL Davidson H Decousus A Gallus AW Lensing F Piovella MH Prins HR Buller 2009 Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials Thromb Haemost 101 762 769 19350123
12. BH Chong A Isaacs 2009 Heparin-induced thrombocytopenia: what clinicians need to know Thromb Haemost 101 279 283 1:CAS:528:DC%2BD1MXjtVyrtbw%3D 19190810
13. AE Handschin OA Trentz SP Hoerstrup HJ Kock GA Wanner O Trentz 2005 Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro Br J Surg 92 177 183 10.1002/bjs.4809 1:CAS:528:DC%2BD2MXisVehtbw%3D 15584059 (Pubitemid 40269331)
14. M Bhandari J Hirsh JI Weitz E Young TJ Venner SG Shaughnessy 1998 The effects of standard and low molecular weight heparin on bone nodule formation in vitro Thromb Haemost 80 413 417 1:CAS:528:DyaK1cXmtFCls7w%3D 9759620
15. R Rajgopal M Butcher JI Weitz SG Shaughnessy 2006 Heparin synergistically enhances interleukin-11 signalling through up-regulation of the MAPK pathway J Biol Chem 281 20780 20787 10.1074/jbc.M600169200 1:CAS:528:DC%2BD28Xnt1Gqt7k%3D 16720575 (Pubitemid 44115419)
16. JM Muir J Hirsh JI Weitz M Andrew E Young SG Shaughnessy 1997 A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats Blood 89 3236 3242 1:CAS:528: DyaK2sXivVyitLY%3D 9129028
17. D Hawkins J Evans 2005 Minimizing the risk of heparin-induced osteoporosis during pregnancy Expert Opin Drug Saf 4 583 590 10.1517/14740338.4.3.583 1:CAS:528:DC%2BD2MXlsFaktrk%3D 15934862 (Pubitemid 40723729)
18. TE Warkentin RJ Cook VJ Marder JA Sheppard JC Moore BI Eriksson A Greinacher JG Kelton 2005 Anti-platelet factor 4/heparin antibodies in orthopaedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood 106 3791 3796 10.1182/blood-2005-05-1938 1:CAS:528:DC%2BD2MXht12ksbbP 16109780 (Pubitemid 41739014)
19. L Rauova M Poncz SE McKenzie MP Reilly G Arepally JW Weisel C Nagaswami DB Cines BS Sachais 2005 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia Blood 105 131 138 10.1182/blood-2004-04-1544 1:CAS:528:DC%2BD2MXis1GrsQ%3D%3D 15304392 (Pubitemid 40053074)
20. A Greinacher M Gopinadhan JU Gunther MA Omer-Adam U Strobel TE Warkentin G Papastavrou W Weitschies CA Helm 2006 Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies Arterioscler Thromb Vasc Biol 26 2386 2393 10.1161/01.ATV. 0000238350.89477.88 1:CAS:528:DC%2BD28XpsVOqt74%3D 16873726 (Pubitemid 44465738)
21. B Lobo C Finch A Howard S Minhas 2008 Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia Thromb Haemost 99 208 214 1:CAS:528:DC%2BD1cXhtlWis70%3D 18217156
22. Blackmer AB, Oertel MD, Valgus JM (2009) Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues (October). Ann Pharmacother [Epub ahead of print]
23. DB Blossom AJ Kallen PR Patel A Elward L Robinson G Gao R Langer KM Perkins JL Jaeger KM Kurkjian M Jones SF Schillie N Shehab D Ketterer G Venkataraman TK Kishimoto Z Shriver AW McMahon KF Austen S Kozlowski A Srinivasan G Turabelidze CV Gould MJ Arduino R Sasisekharan 2008 Outbreak of adverse reactions associated with contaminated heparin N Engl J Med 359 2674 2684 10.1056/NEJMoa0806450 1:CAS:528:DC%2BD1cXhsFaks7vL 19052120
24. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators S Yusuf SR Mehta S Chrolavicius R Afzal J Pogue CB Granger A Budaj RJ Peters JP Bassand L Wallentin C Joyner KA Fox 2006 Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 1464 1476 10.1056/NEJMoa055443 1:CAS:528:DC%2BD28XjtFWhuro%3D 16537663
25. S Yusuf SR Mehta S Chrolavicius R Afzal J Pogue CB Granger A Budaj RJ Peters JP Bassand L Wallentin C Joyner KA Fox OASIS-6 Trial Group 2006 Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 1519 1530 10.1001/jama.295.13.joc60038 1:CAS:528:DC%2BD28Xjt12isbs%3D 16537725
26. SR Mehta CB Granger JW Eikelboom JP Bassand L Wallentin DP Faxon RJ Peters A Budaj R Afzal S Chrolavicius KA Fox S Yusuf 2007 Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial J Am Coll Cardiol 50 1742 1751 10.1016/j.jacc.2007.07.042 1:CAS:528: DC%2BD2sXht1aktL3O 17964037 (Pubitemid 47600591)
27. EM Wiebe AR Stafford JC Fredenburgh JI Weitz 2003 Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide J Biol Chem 278 35767 35774 10.1074/jbc.M304803200 1:CAS:528:DC%2BD3sXntVajtr4%3D 12832413 (Pubitemid 37102353)
28. L Yang C Manithody AR Rezaie 2007 Localization of the heparin binding exosites of factor IXa J Biol Chem 277 50756 50760 10.1074/jbc.M208485200
29. T Bedsted R Swanson YJ Chuang PE Bock I Bjork ST Olson 2003 Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites Biochemistry 42 8143 8152 10.1021/bi034363y 1:CAS:528:DC%2BD3sXks12nurc%3D 12846563 (Pubitemid 36858975)
30. HR Buller BL Davidson H Decousus A Gallus M Gent F Piovella MH Prins G Raskob AE van den Berg-Segers R Cariou O Leeuwenkamp AW Lensing Matisse Investigators 2003 Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 1695 1702 10.1056/NEJMe038112 1:STN:280:DC%2BD3srgvF2nuw%3D%3D 14585937 (Pubitemid 36976003)
31. HR Buller BL Davidson H Decousus A Gallus M Gent F Piovella MH Prins G Raskob AE Segers R Cariou O Leeuwenkamp AW Lensing Matisse Investigators 2004 Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial Ann Intern Med 140 867 873 15172900
32. BI Eriksson KA Bauer MR Lassen AG Turpie Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study 2001 Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery N Engl J Med 345 1298 1304 10.1056/NEJMoa011100 1:CAS:528: DC%2BD3MXnvV2ltr0%3D 11794148
33. BI Eriksson MR Lassen PENTasaccharide in Hip-FRActure Surgery Plus Investigators 2003 Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study Arch Intern Med 163 1337 1342 10.1001/archinte.163.11.1337 1:CAS:528:DC%2BD3sXltVSntrs%3D 12796070 (Pubitemid 36676199)
34. W Lim F Dentali JW Eikelboom MA Crowther 2006 Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Ann Intern Med 144 673 684 1:CAS:528:DC%2BD28Xlt1artbg%3D 16670137
35. C Kearon JS Ginsberg JA Julian J Douketis S Solymoss P Ockelford S Jackson AG Turpie B MacKinnon J Hirsh M Gent Fixed-Dose Heparin (FIDO) Investigators 2006 Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism JAMA 296 935 942 10.1001/jama.296.8.935 1:CAS:528: DC%2BD28XoslOqtLg%3D 16926353 (Pubitemid 44285370)
36. RA Raschke BM Reilly JR Guidry JR Fontana S Srinivas 1993 The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial Ann Intern Med 119 874 881 1:STN:280:DyaK2c%2FivVeqsg%3D%3D 8214998
37. JM Gawoski CF Arkin T Bovill J Brandt WA Rock Jr DA Triplett 1987 The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects Arch Pathol Lab Med 111 785 790 1:STN:280:DyaL2szisFGjtg%3D%3D 3632297
38. SM Bates JI Weitz M Johnston J Hirsh JS Ginsberg 2001 Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin Arch Intern Med 161 385 391 10.1001/archinte.161.3.385 1:CAS:528:DC%2BD3MXht1WjsL8%3D 11176764
39. MN Levine J Hirsh M Gent AG Turpie M Cruickshank J Weitz D Anderson M Johnston 1994 A randomized trial comparing activated thromboplastin time with heparin assays in patients with acute venous thromboembolism requiring large daily doses of heparin Arch Intern Med 154 49 56 10.1001/archinte.154.1.49 1:STN:280:DyaK2c%2FptF2iug%3D%3D 8267489 (Pubitemid 24018101)
40. th edition) Chest 133 340S 380S 10.1378/chest.08-0677 1:CAS:528:DC%2BD1cXptVKhsro%3D 18574270
41. P Savi JP Herault P Duchaussoy L Millet P Schaeffer M Petitou F Bono JM Herbert 2008 Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy J Thromb Haemost 6 1697 1706 10.1111/j.1538-7836.2008.03089.x 1:CAS:528:DC%2BD1cXhtlaitLvI 18647228
42. HR Buller AT Cohen B Davidson H Decousus AS Gallus M Gent G Pillion F Piovella MH Prins GE Raskob 2007 Idraparinux versus standard therapy for venous thromboembolic disease N Engl J Med 357 1094 1104 10.1056/NEJMoa064247 1:CAS:528:DC%2BD2sXhtVKgtLzK 17855670 (Pubitemid 47443214)
43. HR Buller AT Cohen B Davidson H Decousus AS Gallus M Gent G Pillion F Piovella MH Prins GE Raskob 2007 Extended prophylaxis of venous thromboembolism with idraparinux N Engl J Med 357 1105 1112 10.1056/NEJMoa067703 1:CAS:528:DC%2BD2sXhtVKgtLzL 17855671 (Pubitemid 47443215)
44. MG Bousser J Bouthier HR Buller AT Cohen H Crijns BL Davidson J Halperin G Hankey S Levy V Pengo P Prandoni MH Prins W Tomkowski C Thorp-Pedersen DG Wyse 2008 Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label non-inferiority trial Lancet 371 315 321 10.1016/S0140-6736(08)60168-3 1:STN:280:DC%2BD1c7js1Gmsg%3D%3D 18294998
45. JI Weitz J Hirsh MM Samama American College of Chest Physicians 2008 New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 234S 256S 10.1378/chest.08-0673 1:CAS:528:DC%2BD1cXptVKiu7Y%3D 18574267
46. KR Guertin YM Choi 2007 The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development Curr Med Chem 14 2471 2481 10.2174/092986707782023659 1:CAS:528:DC%2BD2sXhtVKqtrnE 17979700 (Pubitemid 47618035)
47. JW Eikelboom JI Weitz 2009 Otamixaban in acute coronary syndromes Lancet 374 762 764 10.1016/S0140-6736(09)61529-4 19717186
48. MS Sabatine EM Antman P Widimsky IO Ebrahim RG Kiss A Saaiman R Polasek CF Contant CH McCabe E Braunwald 2009 Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-AC1 TIMI42): a randomized, double-blind, active-controlled, phase 2 trial Lancet 374 787 795 10.1016/S0140-6736(09)61454-9 1:CAS:528:DC%2BD1MXhtV2ksLnK 19717184
49. CK Dyke SR Steinhubl NS Kleiman RO Cannon LG Aberle M Lin SK Myles C Melloni RA Harrington JH Alexander RC Becker CP Rusconi 2006 First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2490 2497 10.1161/CIRCULATIONAHA.106.668434 1:CAS:528:DC%2BD28Xht1Cqur3M 17101847
50. MY Chan MG Cohen CK Dyke SK Myles LG Aberle M Lin J Walder SR Steinhubl IC Gilchrist NS Kleiman DA Vorchheimer N Chronos C Melloni JH Alexander RA Harrington RM Tonkens RC Becker CP Rusconi 2008 Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Circulation 117 2865 2874 10.1161/CIRCULATIONAHA.107. 745687 1:CAS:528:DC%2BD1cXmsVOjsL0%3D 18506005
51. PL Gross JI Weitz 2009 New antithrombotic drugs Clin Pharmacol Therap 86 139 146 10.1038/clpt.2009.98 1:CAS:528:DC%2BD1MXovFOrsbs%3D